Calliditas announces submission of new drug application to U.S. FDA for Nefecon in patients with primary IgA nephropathy

15 March 2021 -  Calliditas Therapeutics today announced the submission of a new drug application to the U.S. FDA for ...

Read more →

Marius Pharmaceuticals receives PDUFA date for Kyzatrex NDA for treatment of hypogonadism

11 March 2021 - Marius Pharmaceuticals announced today that the U.S. FDA has assigned a Prescription Drug User Fee Act goal ...

Read more →

Revolutionary option for medical device sterilisation approved by FDA

11 March 2021 - The United States FDA newly approved chlorine dioxide gas for contract sterilisation of medical devices.  ...

Read more →

Berlin Heals receives breakthrough device designation from FDA for its C-MIC heart failure device and initiates early feasibility study in the United States

11 March 2021 - Berlin Heals announced today that the US FDA has granted a breakthrough device designation for its ...

Read more →

Denali Therapeutics announces fast track designation granted by the U.S. FDA to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome

11 March 2021 - Denali Therapeutics  today announced that the U.S. FDA has granted fast track designation to ETV:IDS (DNL310) for ...

Read more →

FDA grants fast track designation to Spectrum Pharmaceuticals’ poziotinib

11 March 2021 - Spectrum Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for poziotinib for the ...

Read more →

FDA grants breakthrough device designation for Inivata’s RaDaR assay

9 March 2021 - Designation will help accelerate the regulatory path of RaDaR for use in detection of minimal residual ...

Read more →

Kadmon announces U.S. FDA has extended the review period for belumosudil in chronic graft versus host disease

10 March 2021 - Kadmon today announced that the U.S. FDA has extended the review period for the new drug application ...

Read more →

AVEO Oncology announces U.S. FDA approval of Fotivda (tivozanib) for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma

10 March 2021 - AVEO plans to make Fotivda available to patients in the U.S. by 31 March 2021. ...

Read more →

Vertex announces FDA fast track designation and initiation of a Phase 1/2 clinical trial for VX-880, a novel investigational cell therapy for the treatment of type 1 diabetes

10 March 2021 - VX-880 is the first investigational stem cell derived therapy utilising fully differentiated, insulin-producing pancreatic islet cells for ...

Read more →

FDA accepts the new drug application for review of Idorsia’s daridorexant for the treatment of adult patients with insomnia

10 March 2021 - The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on ...

Read more →

U.S. FDA accepts UVision360 submission for novel Luminelle DTx system biopsy sheath

9 March 2021 - UVision360 announces today that the U.S. FDA has accepted the Company's submission to expand the Luminelle DTx ...

Read more →

Rocket Pharmaceuticals receives FDA regenerative medicine advanced therapy designation for RP-L201 gene therapy for leukocyte adhesion deficiency-I

9 March 2021 - Enrollment complete in Phase 1/2 clinical trial of RP-L201 for the treatment of LAD-I. ...

Read more →

Seqirus announces U.S. FDA approval of expanded age indication of its cell based quadrivalent influenza vaccine for people two years of age and older

5 March 2021 - Seqirus today announced that the U.S. FDA has approved Flucelvax Quadrivalent (influenza vaccine), the company's cell-based quadrivalent ...

Read more →

Biden’s silence on an FDA nominee underscores how tough it is to fill that job

9 March 2021 - Nearly everyone here expected President Biden to move with record speed to nominate someone to lead ...

Read more →